Patents Assigned to Inserm
  • COMBINED USE OF A TRKA INHIBITOR AND AN EPHA2 INHIBITOR FOR USING IN THE TREATMENT OF SOLID CANCERS, AND METHOD FOR THE PROGNOSIS OF SURVIVAL OF A PATIENT WHO HAS A SOLID CANCER
    Publication number: 20170258871
    Abstract: The invention relates to an EphA2 inhibitor for the use thereof in the treatment of solid cancer treated with a TrkA inhibitor, and a TrkA inhibitor for the use thereof in the treatment of solid cancer treated with an EpbA2 inhibitor. The invention also relates to a method for the prognosis of survival of a patient who has a solid cancer, comprising a step of detecting the expression of TrkA and EphA2 in a biological sample of the patient, the co-expression of TrkA and EphA2 being associated with a poor prognosis of survival of the patient.
    Type: Application
    Filed: September 7, 2015
    Publication date: September 14, 2017
    Applicants: UNIVERSITE DES SCIENCES ET TECHNOLOGIES DE LILLE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Robert Toillon, Xuefen Le Bourhis, Cyril Corbet, Leo Aubert, Matthieu Guilbert
  • Methods for determining human sperm quality
    Patent number: 9759728
    Abstract: The present invention relates generally to the fields of reproductive medicine. More specifically, the present invention relates to methods and kits for determining the human sperm quality.
    Type: Grant
    Filed: September 4, 2014
    Date of Patent: September 12, 2017
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de Droit et de la Sante de Lille 2, Centre Hospitalier Regional Universitaire de Lille
    Inventors: Nicolas Sergeant, Valerie Mitchell, Fanny Jumeau, Julien Sigala
  • Porous polysaccharide scaffold comprising nano-hydroxyapatite and use for bone formation
    Patent number: 9757494
    Abstract: The present invention relate to three dimensional porous polysaccharide matrices able to induce mineralisation of a tissue in osseous site, as well as in non-osseous site, in the absence of stent cells or growth factors.
    Type: Grant
    Filed: June 2, 2015
    Date of Patent: September 12, 2017
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de Bordeaux II Victor Segalen, Universite Paris Diderot-Paris 7
    Inventors: Joelle Amedee, Didier Letourneur, Catherine Le Visage, Sidi Mohammed Derkaoui, Jean-Christophe Fricain, Sylvain Catros
  • NITROGEN-CONTAINING ANALOGS OF SALINOMYCIN, SYNTHESIS AND USE AGAINST CANCER STEM CELLS AND MALARIA
    Publication number: 20170253610
    Abstract: The present invention concerns compounds of formula (I), enantiomers, mixture of enantiomers, diastereoisomers and mixture of diasteroisomers thereof formula (I): wherein at least one of W, X and Y is selected from the group consisting of —NR1R2; —NR3—(CH2)n—NR4R5; —O—(CH2)n—NR4R5; —NR3—(CH2)n—N?R6R7R8; and —O—(CH2)n—N?R6R7R8 and Z is a functional group capable of chelating iron salts. The present invention also concerns the compounds of formula (I) for use as a drug, in particular, in the treatment of cancer and malaria.
    Type: Application
    Filed: September 14, 2015
    Publication date: September 7, 2017
    Applicants: Centre National de la Recherche Scientifique (CNRS), Institut National de la Sante et de la Recherche M edicale (INSERM), Universite Paris Descartes, Uiversite Paris-SUD
    Inventors: Maryam Mehrpour, Raphael Rodriguez, Antje Hienzsch, Mai Trang, Ahmed Hamai
  • In vitro modelling of haematopoietic stem cell medullary nests: a tool for studying the regulation of haematopoiesis, evaluating the nesting potential of a haematopoietic graft and testing the pharmacotoxicology of medicaments
    Patent number: 9752121
    Abstract: The present invention relates to a culture support for cultivating hematopoietic stem cells (HSCs) and/or hematopoietic progenitors (HPs), comprising a calcium biomaterial, osteoclasts, endothelial cells and mesenchymatous stem cells (MSCs) and/or osteoblasts and/or adipocytes. The present invention also relates to a method for preparing such a culture support, and an in vitro HSC and/or HP cultivation method. The use of such a culture support for studying cellular mechanisms involved in hematopoiesis and/or differentiation of HSC/HPs and/or for studying the efficacy and/or the toxicity of a medicament candidate is also described.
    Type: Grant
    Filed: August 14, 2012
    Date of Patent: September 5, 2017
    Assignees: ETAT FRANCAIS (MINISTERE DE LA DEFENSE), SERVICE DE SANTE DES ARMEES, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Jean-Jacques Lataillade, Marie-Caroline Le Bousse-Kerdiles
  • Tetrahydroquinoline derivatives and their use as Epac inhibitors
    Patent number: 9751838
    Abstract: The invention relates to tetrahydroquinoline derivatives and their use in the treatment and/or the prevention of a disease wherein the Epac protein is involved, such as inflammation, cancer, vascular diseases, kidney diseases, cognitive disorders and cardiac diseases.
    Type: Grant
    Filed: September 17, 2013
    Date of Patent: September 5, 2017
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paul Sabatier Toulouse III, Universite Paris-Sud, Universite d'Orleans
    Inventors: Frank Lezoualc'h, Rodolphe Fischmeister, Malik Bisserier, Pascal Bouyssou, Jean-Paul Blondeau, Delphine Courilleau
  • Use Of SCO-Spondin Peptides For Inhibiting Or Preventing Neuronal Apoptosis Mediated By Cell Death Receptor Ligands
    Publication number: 20170246247
    Abstract: The invention relates to a polypeptide derived from the TSR (thrombospondin type 1 units) of SCO-Spondin for inhibiting or preventing apoptosis mediated by the cell death receptor ligands, such as TRAIL or FasL. The polypeptide of the invention comprises a sequence -W-S-A1-C-S-A2-C-G- wherein A1 and A2 are amino acid sequences comprising 1 to 5 amino acids. More particularly, the invention relates to said polypeptide for inhibiting or preventing the apoptosis associated with a disease selected from the group consisting of neurodegenerative disorders, cerebral ischemia, neuronal traumas, neuronal inflammatory diseases, and viral neurodegenerations.
    Type: Application
    Filed: March 8, 2017
    Publication date: August 31, 2017
    Applicant: Institut National de la Sante et de la Recherche Medicate (INSERM)
    Inventors: Annie Meiniel, Fabrice Lalloue, Marie-Odile Jauberteau
  • Method for detecting the interaction of at least one entity with a dielectric layer
    Patent number: 9746460
    Abstract: The invention relates to a method of detecting the interaction between at least one entity and a dielectric layer containing different electron levels in the energy band gap of the dielectric layer, the method comprising the following steps: a) depositing the entity on the dielectric layer; b) subjecting the dielectric layer and the entity deposited thereon to exciting electromagnetic radiation that does not give rise to observable luminescence in the entity itself under the conditions implemented in step c); and c) detecting the luminescence of the dielectric layer, in which the radiative and non-radiative electron transitions between the energy levels of the band gap have been influenced as a result of its interaction with the entity.
    Type: Grant
    Filed: October 8, 2012
    Date of Patent: August 29, 2017
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: Tetyana Nichiporuk, Tetiana Serdiuk, Volodymyr Lysenko, Yuriy Zakharko, Alain Geloen, Mustapha Lemiti
  • COMPOSITIONS USEFUL IN THE DIAGNOSTIC OF LATENTLY INFECTED MYCOBACTERIUM TUBERCULOSIS
    Publication number: 20170242038
    Abstract: The present invention concerns a composition comprising at least three peptides derived from Mycobacterium tuberculosis antigen Rv2626c, its use in the diagnostic of latently infected Mycobacterium tuberculosis (LTBI) subjects, corresponding methods of use and kits.
    Type: Application
    Filed: August 28, 2015
    Publication date: August 24, 2017
    Applicants: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.), CONICET (CONSEJO NACIONAL DE INVESTIGACIONES CIENTIFICAS Y TECNICAS), INSTITUT JEAN PAOLI & IRENE CALMETTES, UNIVERSITÉ D'AIX-MARSEILLE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Juan IOVANNA, Virginia PASQUINELLI, Maria Madgalena GHERARDI, Hector Eduardo CHULUYAN, Ana Inès ROVETTA, Delfina PENA, Véronica Edith GARCIA
  • Therapeutic probe for treating tissue using focused intersecting ultrasonic waves
    Patent number: 9737324
    Abstract: A therapeutic probe having a transducer for focusing the ultrasonic waves into a first focal area, the emission surface of which has, within a profile plane, two concave curve segments which have a finite length and which are symmetrical relative to a plane of symmetry, or to an axis of symmetry. Within the profile plane, both concave curve segments extend along arcs of first and second non-coincident circles that intersect each other, and each curve segment has an acoustic axis intersecting the axis of symmetry, or the plane of symmetry, between the first focal area and the emission surface, the acoustic axes being spaced apart from each other such that the beams from the emission surface intersect each other so as to create a second focal area located in and situated between the first focal area and the emission surface.
    Type: Grant
    Filed: March 15, 2012
    Date of Patent: August 22, 2017
    Assignees: EDAP TMS FRANCE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE)
    Inventors: David Melodelima, Jeremy Vincenot, Emmanuel Blanc, Jean-Yves Chapelon
  • Pharmaceutical compositions for preventing glucocorticoid-induced skin thinning
    Patent number: 9730948
    Abstract: The present invention relates to method and pharmaceutical compositions for preventing glucocorticoid-induced corneal or skin thinning. In particular, the present invention relates to a mineralocorticoid receptor antagonist for topical use in a method for preventing or reducing glucocorticoid-induced corneal or skin thinning in a subject in need thereof. The invention also relates to a topical pharmaceutical composition comprising an amount of at least one glucocorticoid and an amount of at least one mineralocorticoid receptor antagonist or inhibitor of MR expression for use in a method for treating an inflammatory skin disease or an inflammatory disease of the cornea or of the anterior segment of the eye in a subject in need thereof.
    Type: Grant
    Filed: June 20, 2014
    Date of Patent: August 15, 2017
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE PARIS DESCARTES, UNIVERSITE PIERRE ET MARIE CURIE (PARIS 6), ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP)
    Inventors: Nicolette Farman, Frederic Jaisser, Francine Behar-Cohen, Selin Aractingi, Van Tuan Nguyen
  • 3-(4?-substituted)-benzyl-ether derivatives of pregnenolone
    Patent number: 9732115
    Abstract: The invention relates to a compound of Formula (I), or a pharmaceutically acceptable salt thereof: wherein R1 is C1-8 alkyl, C1-8 alkoxy, CN, NO2, amino, COOH, COOCH3, OH, N3, or halogen and R2 is H, OH, C1-8 alkyl, C1-8 alkoxy, C2-C6 alkenyl, halogen, Bn-O—, Bn- optionally substituted, or Ph- optionally substituted.
    Type: Grant
    Filed: November 27, 2013
    Date of Patent: August 15, 2017
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), SC BELENOS, Universite de Bordeaux
    Inventors: Pier Vincenzo Piazza, Monique Vallee, Francois-Xavier Felpin, Jean-Michel Revest, Sandy Fabre
  • Mutated tissue plasminogen activators and uses thereof
    Patent number: 9732334
    Abstract: The present invention relates to mutated tissue plasminogen activators, and their use for treating thrombotic diseases.
    Type: Grant
    Filed: December 17, 2015
    Date of Patent: August 15, 2017
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de Caen Basse Normandie
    Inventors: Denis Vivien, Jerome Parcq
  • Aptamers inhibiting the enzymatic activity of tyrosinase
    Patent number: 9732348
    Abstract: The invention relates to a DNA aptamer that can inhibit the enzymatic activity of tyrosinase for the conversion of tyrosine into L-DOPA and dopaquinone, and to the dermatological and cosmetic uses thereof.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: August 15, 2017
    Assignees: L V M H Recherché, Institut National de la Sante et de la Recherche Medicale (INSERM)
    Inventors: Jean Hubert Cauchard, Robin Kurfurst, Sylvianne Schnebert, Eric Dausse, Jean-Jacques Toulme
  • HPV particles and uses thereof
    Patent number: 9724404
    Abstract: The invention relates to modified HPV particles that can be used therapeutically. Modified HPV particles may be used to deliver therapeutic agents, including siRNA molecules. Modified HPV particles may be used for the treatment of diseases or conditions of mucosal tissue, including HPV (human papilloma virus) infection and HPV-related tumors.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: August 8, 2017
    Assignees: INSERM (Institut National de la Santé et de la Recherche Médicale), Aura Biosciences, Inc.
    Inventors: Pierre L. Coursaget, Antoine A. Touzé, Maxime J. J. Fleury, Nicolas Combelas, Elisabet de los Pinos
  • POPULATION OF IMMUNOREGULATORY T CELLS SPECIFIC FOR AN IRRELEVANT ANTIGEN AND USES THEREOF FOR PREVENTING OR TREATING IMMUNE DISEASES
    Publication number: 20170216417
    Abstract: The present invention relates methods and compositions for preventing or treating various immune diseases including graft-versus-host disease (GVHD) using populations or compositions of immunoregulatory T cells specific for an irrelevant antigen; such cells being activated in vivo by a simultaneous, separate or sequential administration of said antigen.
    Type: Application
    Filed: February 7, 2017
    Publication date: August 3, 2017
    Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite Paris Diderot Paris 7, Universite Paris Est Creteil Val De Marne
    Inventors: José Cohen, Gaelle Martin, Sébastein Maury, Benoit Salomon
  • INHIBITORS OF FUSION BETWEEN VIRAL AND CELL MEMBRANES AS WELL AS COMPOSITIONS AND METHODS OF USING THEM
    Publication number: 20170216448
    Abstract: The present application relates to an inhibitor of fusion between a viral membrane from an enveloped virus and a cell membrane, where the viral membrane comprises a fusion mediating protein including a C-terminal peptide. The inhibitor comprises the C-terminal peptide of the fusion mediating protein from an enveloped virus and tocopherol or a derivative or pharmaceutically acceptable salt thereof attached to the C-terminal peptide. Also disclosed is a pharmaceutical composition including the inhibitor as well as methods of inhibiting viral fusion, blocking viral spread, and preventing or treating viral infection, with the inhibitor or pharmaceutical composition.
    Type: Application
    Filed: May 7, 2015
    Publication date: August 3, 2017
    Applicants: Cornell University, Inserm
    Inventors: Matteo POROTTO, Anne MOSCONA, Branka HORVAT, Cyrille MATHIEU
  • CAPPED AND UNCAPPED RNA MOLECULES AND BLOCK COPOLYMERS FOR INTRACELLULAR DELIVERY OF RNA
    Publication number: 20170209597
    Abstract: The present invention relates to the use of at least one tetra functional non-ionic amphiphilic block copolymer as a vehicle for capped or uncapped mRNA for intracellular delivery for gene therapy.
    Type: Application
    Filed: April 1, 2015
    Publication date: July 27, 2017
    Applicants: Institut National de la Sante et de la Recherche Medicale (INSERM), Universite de Nantes, Centre National de la Recherche Scientifique
    Inventor: Bruno Pitard
  • Ionic liquid supported organotin reagents for the manufacturing of radiopharmaceuticals compounds
    Patent number: 9714261
    Abstract: An ionic liquid supported organotin reagent of formula (I) A process for manufacturing the ionic liquid supported organotin reagent of formula (I), a process for manufacturing an halogenated or radio-halogenated compound using compound of formula (I), a device for implementing the halogenating process and a kit including the compound of formula (I) are also described.
    Type: Grant
    Filed: January 7, 2015
    Date of Patent: July 25, 2017
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), UNIVERSITE DE NANTES, UNIVERSITE D' ANGERS, UNIVERSITE DU MAINE, INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), CENTRE HOSPITALIER UNIVERSITAIRE DE NANTES
    Inventors: Stephanie Legoupy, Djibril Faye, Jean-Francois Gestin, Holisoa Rajerison, Alain Faivre-Chauvet, Fabien Boeda
  • Vector particles for targeting CD34+ cells
    Patent number: 9714434
    Abstract: The present invention relates to a vector particle for transferring biological material into cells, wherein said vector particle comprises at least: a first protein which comprises the transmembrane and extracellular domains of the feline endogenous RD114 virus envelope glycoprotein, and a second protein which comprises a ligand of the c-Kit receptor.
    Type: Grant
    Filed: June 10, 2013
    Date of Patent: July 25, 2017
    Assignee: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Francois-Loic Cosset, Els Verhoeyen, Caroline Costa, Cecilia Frecha